ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On June6, 2017, Aralez Pharmaceuticals Inc. (the Company)
received a written letter of resignation (the Resignation Letter)
from Jason M. Aryeh stating that he resigned, effective June7,
2017, from his position on the Board of Directors (the Board) of
the Company. Mr.Aryeh did not resign from the Board as a result
of any current dispute or disagreement with the Company. Mr.Aryeh
was a valued member of the Board during the period he served as a
director.
A copy of the Resignation Letter is filed as Exhibit17.1
to this Current Report on Form8-K, and is incorporated by
reference herein.
In connection with Mr.Aryehs resignation from the Board, the
Compensation Committee of the Board agreed to extend the
expiration date and vesting of Mr.Aryehs options to purchase
shares of the Companys common stock and Restricted Stock Units of
the Company, in each case, until June7, 2018.
Item9.01. Financial Statements and Exhibits
(d)List of Exhibits
|
EXHIBIT NO. |
|
DESCRIPTION |
|
10.1 |
Amendment to Nonqualified Stock Option Award Agreements, |
|
|
10.2 |
Amendment to Restricted Stock Unit Award Agreement, dated |
|
|
17.1 |
Resignation Letter from Jason M. Aryeh, dated June6, 2017 |
About ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ)
Aralez Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine. Fibricor (fenofibric acid) is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia, and as a complementary therapy along with diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG) and apolipoprotein B (Apo B). Fibricor is also used to increase high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia. Cambia (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (NSAID).